In the Search for Biomarkers of Pulmonary Arterial Hypertension, Are Cytokines IL-2, IL-4, IL-6, IL-10, and IFN-Gamma the Right Indicators to Use?
暂无分享,去创建一个
E. Grywalska | M. Tomaszewski | Paulina Mertowska | Sebastian Mertowski | K. Jonas | Agnieszka Styczeń | Martyna Janczewska | Grzegorz Kopeć | Grzegorz Kopeć
[1] E. Grywalska,et al. CTLA-4 Expression Is a Promising Biomarker of Idiopathic Pulmonary Arterial Hypertension and Allows Differentiation of the Type of Pulmonary Hypertension , 2022, International journal of molecular sciences.
[2] M. Humbert,et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. , 2022, European heart journal.
[3] M. Kool,et al. Peripheral Blood T Cells of Patients with IPAH Have a Reduced Cytokine-Producing Capacity , 2022, International journal of molecular sciences.
[4] O. Kann,et al. Priming of microglia by type II interferon is lasting and resistant to modulation by interleukin-10 in situ , 2022, Journal of Neuroimmunology.
[5] E. Grywalska,et al. Role of the Immune System Elements in Pulmonary Arterial Hypertension , 2021, Journal of clinical medicine.
[6] M. Kool,et al. Plasma markers in pulmonary hypertension subgroups correlate with patient survival , 2021, Respiratory Research.
[7] J. Roliński,et al. Overexpression of PD-1 on Peripheral Blood Lymphocytes in Patients with Idiopathic Pulmonary Arterial Hypertension and Its Association with High Viral Loads of Epstein-Barr Virus and Poor Clinical Parameters , 2020, Journal of clinical medicine.
[8] B. Relja,et al. Cytokines in Inflammatory Disease , 2019, International journal of molecular sciences.
[9] S. Archer,et al. Pulmonary arterial hypertension: pathogenesis and clinical management , 2018, British Medical Journal.
[10] T. Thenappan,et al. Interleukin-6 is independently associated with right ventricular function in pulmonary arterial hypertension. , 2017, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[11] K. Tsuchiya,et al. Novel CD200 homologues iSEC1 and iSEC2 are gastrointestinal secretory cell-specific ligands of inhibitory receptor CD200R , 2016, Scientific Reports.
[12] Simon Gibbs,et al. 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. , 2016, Revista espanola de cardiologia.
[13] K. Kamiński,et al. Enhanced IL-6 trans-signaling in pulmonary arterial hypertension and its potential role in disease-related systemic damage. , 2015, Cytokine.
[14] B. Lambrecht,et al. T-helper 17 cell polarization in pulmonary arterial hypertension. , 2015, Chest.
[15] C. Cheadle,et al. Hypoxia-induced mitogenic factor (FIZZ1/RELMα) induces endothelial cell apoptosis and subsequent interleukin-4-dependent pulmonary hypertension. , 2014, American journal of physiology. Lung cellular and molecular physiology.
[16] R. Speich,et al. Inflammatory cytokines in pulmonary hypertension , 2014, Respiratory Research.
[17] Wei Chen,et al. Decreased CD200R expression on monocyte-derived macrophages correlates with Th17/Treg imbalance and disease activity in rheumatoid arthritis patients , 2014, Inflammation Research.
[18] M. Humbert,et al. Proinflammatory cytokine levels are linked to death in pulmonary arterial hypertension , 2013, European Respiratory Journal.
[19] S. Sarin,et al. Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin , 2013, Journal of viral hepatitis.
[20] Chris Cheadle,et al. Hypoxia-induced mitogenic factor (HIMF/FIZZ1/RELMα) in chronic hypoxia- and antigen-mediated pulmonary vascular remodeling , 2013, Respiratory Research.
[21] Dong Woon Kim,et al. Expression of CD200 in alternative activation of microglia following an excitotoxic lesion in the mouse hippocampus , 2012, Brain Research.
[22] D. Knipe,et al. CD200R1 Supports HSV-1 Viral Replication and Licenses Pro-Inflammatory Signaling Functions of TLR2 , 2012, PloS one.
[23] M. Toungouz,et al. Characterization and functionality of the CD200-CD200R system during mesenchymal stromal cell interactions with T-lymphocytes. , 2012, Immunology letters.
[24] S. Halpern,et al. Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry. , 2011, Chest.
[25] R. Trembath,et al. Elevated Levels of Inflammatory Cytokines Predict Survival in Idiopathic and Familial Pulmonary Arterial Hypertension , 2010, Circulation.
[26] S. Dhillon,et al. Irreversible Pulmonary Hypertension Associated with the use of Interferon Alpha for Chronic Hepatitis C , 2010, Digestive Diseases and Sciences.
[27] U. Rot,et al. Pulmonary arterial hypertension associated with interferon beta treatment for multiple sclerosis: a case report , 2009, Multiple sclerosis.
[28] L. Lue,et al. Decreased expression of CD200 and CD200 receptor in Alzheimer's disease: A potential mechanism leading to chronic inflammation , 2009, Experimental Neurology.
[29] E. Mark,et al. Interleukin-6 Overexpression Induces Pulmonary Hypertension , 2009, Circulation research.
[30] U. Ikeda,et al. Interleukin-10 Expression Mediated by an Adeno-Associated Virus Vector Prevents Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats , 2007, Circulation research.
[31] N. Voelkel,et al. Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling. , 2007, American journal of respiratory and critical care medicine.
[32] R. Johns,et al. Hypoxia-induced mitogenic factor has proangiogenic and proinflammatory effects in the lung via VEGF and VEGF receptor-2. , 2006, American journal of physiology. Lung cellular and molecular physiology.
[33] J. Phillips,et al. Molecular Mechanisms of CD200 Inhibition of Mast Cell Activation , 2004, The Journal of Immunology.
[34] M. Humbert,et al. Treatment of pulmonary arterial hypertension. , 2004, The New England journal of medicine.
[35] Joseph H. Phillips,et al. Characterization of the CD200 Receptor Family in Mice and Humans and Their Interactions with CD200 1 , 2003, The Journal of Immunology.
[36] U. Ikeda,et al. Inflammatory cytokines and cardiovascular disease. , 2003, Current drug targets. Inflammation and allergy.
[37] M. Minden,et al. Vascular Events Associated with Alpha Interferon Therapy , 2003, Leukemia & lymphoma.
[38] H. Saito,et al. Induction of endothelin-1 synthesis by IL-2 and its modulation of rat intestinal epithelial cell growth. , 1998, The American journal of physiology.
[39] M. Humbert,et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. , 1995, American journal of respiratory and critical care medicine.
[40] A. Malik,et al. IL-2 induces pulmonary edema and vasoconstriction independent of circulating lymphocytes. , 1989, Journal of immunology.
[41] R. Merchant,et al. Cardiopulmonary effects of recombinant interleukin-2 infusion in sheep. , 1988, Journal of applied physiology.
[42] R. Hendriks,et al. A cellular and molecular view of T helper 17 cell plasticity in autoimmunity. , 2018, Journal of autoimmunity.
[43] A. Torbicki,et al. Changing the strategy of balloon pulmonary angioplasty resulted in a reduced complication rate in patients with chronic thromboembolic pulmonary hypertension. A single-centre European experience. , 2017, Kardiologia polska.
[44] Jun-Ming Zhang,et al. Cytokines, Inflammation, and Pain , 2007, International anesthesiology clinics.